CG
AVDL

Cutler Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Cutler Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,100
Closed -$21K – 4895
2022
Q2 		$21K Sell
4,100
-13,000
-76% -$53.4K ﹤0.01% 2618
2022
Q1 		$54K Buy
+17,100
New +$118K ﹤0.01% 2177
2020
Q2 		– Sell
-6,200
Closed -$13K – 4362
2020
Q1 		$13K Buy
+6,200
New +$47.6K ﹤0.01% 2557
2016
Q4 		– Sell
-21,200
Closed -$10K – 6470
2016
Q3 		$10K Buy
21,200
+16,500
+351% +$216K ﹤0.01% 4184
2016
Q2 		$6K Buy
+4,700
New +$50.1K ﹤0.01% 4700

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Cutler Group's AVDL Position: Q3 2023 in Review

Cutler Group sold out of Avadel Pharmaceuticals (AVDL) in Q3 2023, closing a stake of 800 shares — an estimated $13K sold.

Cutler Group first reported a position in AVDL in Q1 2016 and held it in 12 quarters. The position peaked at $263K in Q3 2016. 99 funds tracked by Wall St. Rank hold AVDL as of Q3 2023.

  • Cutler Group reported no remaining Avadel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 800 Avadel Pharmaceuticals shares in Q3 2023, an estimated $13K.
  • Cutler Group first reported a position in Avadel Pharmaceuticals in Q1 2016 and held it in 12 quarters.
  • Cutler Group's Avadel Pharmaceuticals position peaked at $263K in Q3 2016.
  • 99 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.